Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 3

Status

Unknown 13Recruiting 8Not yet recruiting 8Terminated 7Completed 6Withdrawn 2Suspended 1

Sponsor Class

OTHER 8

Study Type

Interventional 8

Sponsor

Cancer Type

Breast 7

Conditions

Triple Negative Breast Neoplasms 5Breast Neoplasms 3Neoadjuvant Therapy 1BRCA-Mutated Breast Carcinoma 1

Interventions

pembrolizumab 563Specimen Handling 493Carboplatin 451Magnetic Resonance Spectroscopy 444Cyclophosphamide 418Cisplatin 405Radiotherapy 353Bevacizumab 314Gemcitabine 313Paclitaxel 298Biopsy 292Drug Therapy 284Blood Specimen Collection 248Capecitabine 246Oxaliplatin 241fludarabine 239Nivolumab 234venetoclax 221Injections 213Docetaxel 211Fluorouracil 206Dexamethasone 188Radiosurgery 182Standard of Care 159Rituximab 159Pemetrexed 156Surgical Procedures, Operative 148atezolizumab 146durvalumab 145Leucovorin 140

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
Recruiting × famitinib × Clear all
NCT05582499 2026-05-28

FASCINATE-N

Fudan University

Phase 2 Recruiting
716 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05749588 2026-04-16

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Fudan University

Phase 2 Recruiting
120 enrolled
Breast

Triple Negative Breast Neoplasms

NCT06649331 2026-04-08

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Fudan University

Phase 2 Recruiting
160 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06913777 2025-06-06

Neoadjuvant SNF Precision Therapy Phase III

Fudan University

Phase 3 Recruiting
404 enrolled

Neoadjuvant Therapy

NCT06516289 2024-12-12

Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab

Fudan University

Phase 2 Recruiting
130 enrolled
Breast

BRCA-Mutated Breast Carcinoma

NCT05594095 2024-10-04

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Fudan University

Phase 2 Recruiting
620 enrolled
Breast

Breast Neoplasms

NCT05999149 2024-02-21

BCTOP-T-N01

Fudan University

Phase 3 Recruiting
424 enrolled
Breast

Triple Negative Breast Neoplasms

NCT05760378 2024-02-06

Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.

Fudan University

Phase 3 Recruiting
223 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡